Cancer serum biomarkers based on aberrant post-translational modifications of glycoproteins: Clinical value and discovery strategies

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1856, Issue 2, 2015, Pages 165-177

  Silva, M Luísa S ^a  

^a UNIVERSIDAD AUTÓNOMA DEL ESTADO DE HIDALGO   (Mexico)

Author keywords

Aberrant glycosylation; Cancer biomarkers; Discovery; Glycoproteins; Serum

Indexed keywords

ALPHA FETOPROTEIN; AUTOANTIBODY; BIOLOGICAL MARKER; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GLYCAN; GLYCOGEN; GLYCOPROTEIN; LACTATE DEHYDROGENASE; LECTIN; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; THYROGLOBULIN; TRASTUZUMAB; TUMOR MARKER;

BIOSYNTHESIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CARBOHYDRATE ANALYSIS; CARCINOGENESIS; COLON CANCER; GEL ELECTROPHORESIS; GERM CELL TUMOR; HUMAN; LIQUID CHROMATOGRAPHY; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MASS SPECTROMETRY; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN MICROARRAY; PROTEIN PROCESSING; REVIEW; TESTIS CANCER; THYROID CANCER; THYROID MEDULLARY CARCINOMA; BLOOD; NEOPLASMS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

BIOMARKERS, TUMOR; GLYCOPROTEINS; HUMANS; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84939785631     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2015.07.002     Document Type: Review

References (94)

1. Jones H.B. On a new substance occurring in the urine with mollities ossium. Philos. Trans. R. Soc. Lond. 1848, 138:55-62.
2. Kulasingam V., Diamandis E.P. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat. Clin. Pract. Oncol. 2008, 5:588-599.
3. Lis H., Sharon N. Protein glycosylation. Structural and functional aspects. Eur. J. Biochem. 1993, 218:1-27.
4. Varki A., Cummings R., Esko J., Freeze H., Hart G., Marth J. Essentials in Glycobiology 1999, 85-100. Cold Harbor Laboratory Press, New York.
5. Sears P., Wong C.H. Enzyme action in glycoprotein synthesis. Cell. Mol. Life Sci. 1998, 54:223-252.
6. Brooks S.A., Carter T.M., Royle L., Harvey D.J., Fry S.A., Kinch C., et al. Altered glycosylation of proteins in cancer: what is the potential for new anti-tumour strategies. Anticancer Agents Med. Chem. 2008, 8:2-21.
7. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc. Natl. Acad. Sci. 2002, 99:10231-10233.
8. Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv. Exp. Med. Biol. 2001, 491:369-402.
9. Yousefi S., Higgins E., Daoling Z., Pollex-Kruger A., Hindsgaul O., Dennis J.W. Increased UDP-GlcNAc:Galβ1-3GalNAc-R (GlcNAc to GalNAc) β-1,6-N-acetylgalactosaminyltransferase activity in metastatic murine tumor cell lines. Control of polylactosamine synthesis. J. Biol. Chem. 1991, 266:1772-1782.
10. Freire T., Bay S., von Mensdorff-Pouilly S., Osinaga E. Molecular basis of incomplete O-glycan synthesis in MCF-7 breast cancer cells: putative role of MUC6 in Tn antigen expression. Cancer Res. 2005, 65:7880-7887.
11. Brooks S.A. The involvement of Helix pomatia lectin (HPA) binding N-acetylgalactosamine glycans in cancer progression. Histol. Histopathol. 2000, 15:143-158.
12. Lebrilla C.B., An H.J. The prospects of glycan biomarkers for the diagnosis of diseases. Mol. Biosyst. 2009, 5:17-20.
13. Chapman C., Murray A., Chakrabarti J., Thorpe A., Woolston C., Sahin U., et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann. Oncol. 2007, 18:868-873.
14. Lu H., Ladd J., Feng Z., Wu M., Goodell V., Pitteri S.J., et al. Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in pre-diagnostic breast cancer sera. Cancer Prev. Res. (Phila) 2012, 5:1036-1043.
15. Zhong L., Ge K., Zu J.C., Zhao L.H., Shen W.K., Wang J.F., et al. Autoantibodies as potential biomarkers for breast cancer. Breast Cancer Res. 2008, 10:R40.
16. Wang Z., Tian Y. Clinical value of serum tumor markers CA 19-9, CA 125 and CA 72-4 in the diagnosis of pancreatic carcinoma. Mol. Clin. Oncol. 2014, 2:265-268.
17. Zhong L., Coe S.P., Stromberg A.J., Khattar N.H., Jett J.R., Hirschowitz E.A. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J. Thorac. Oncol. 2006, 1:513-519.
18. Chapman C.J., Healey G.F., Murray A., Boyle P., Robertson C., Peek L.J., et al. Early CDT-lung test: improved clinical utility through additional autoantibody assays. Tumour Biol. 2012, 33:1319-1326.
19. Pedersen J.W., Gentry-Maharaj A., Fourkala E.-O., Dawnay A., Burnell M., Zaikin A., et al. Early detection of cancer in the general population - a blinded case control study of p53 auto-antibodies in colorectal cancer. Br. J. Cancer 2013, 108:107-114.
20. Burford B., Gentry-Maharaj A., Graham R., Allen D., Pedersen J.W., Nudelman A.S., et al. Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer. Br. J. Cancer 2013, 108:2045-2055.
21. Desmetz C., Mange A., Maudelonde T., Solassol J. Autoantibody signatures: progress and perspectives for early cancer detection. J. Cell. Mol. Med. 2011, 15:2013-2024.
22. Springer G.F. Immunoreactive T, and Tn epitopes in cancer diagnosis, prognosis and immunotherapy. J. Mol. Med. 1997, 75:594-602.
23. Desai P.R. Immunoreactive T, and Tn antigens in malignancy: role in carcinoma diagnosis, prognosis, and immunotherapy. Transfus Med. Rev. 2000, 14:312-325.
24. Baskies A.M., Chretien P.B., Weiss J.F., Makuch R.W., Beveridge R.A., William A.B., et al. Serum glycoproteins in cancer patients: first report of correlations with in vitro and in vivo parameters of cellular immunity. Cancer 1980, 45:3050-3060.
25. Rusling J.F., Kumar C.V., Gutkind J.S., Patel V. Measurement of biomarker proteins for point-of-care early detection and monitoring of cancer. Analyst 2010, 135:2496-2511.
26. Ingvarsson J., Wingren C., Carlsson A., Ellmark P., Wahren B., Engström G., et al. Detection of pancreatic cancer using antibody microarray-based serum protein profiling. Proteomics 2008, 8:2211-2219.
27. Carlsson A., Wingren C., Ingvarsson J., Ellmark P., Baldertorp B., Fernö M., et al. Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays. Eur. J. Cancer 2008, 44:472-480.
28. Yim E.K., Park J.S. Role of proteomics in translational research in cervical cancer. Expert Rev. Proteomics 2006, 3:21-36.
29. Almeida J.R.C., Pedrosa N.L., Leite J.B., Fleming T.R.P., Carvalho V.H., Cardoso A.A.A. Tumor markers: a literature review. Rev. Bras. Cancerol. 2007, 53:305-316.
30. Marella S. Prognostic and predictive markers in early detection of different types of cancers for selected organ sites. IOSR J. Pharm. Biol. Sci. 2013, 8:25-42.
31. Guadagni F., Roselli M., Amato T., Cosimelli M., Perri P., Casale V., et al. Cancer Res. 1992, 52:1222-1227.
32. Wang W., Ye L., Li X., Guan S., Sun S., Wang M., et al. Circulating IgG antibody against FOXP3 may be a potential biomarker for lung cancer. Adv. Lung Cancer 2013, 2:79-83.
33. Kurebayashi J. Biomarkers in breast cancer. Gan To Kagaku Ryoho 2004, 31:1021-1026.
34. Cho W.C.S. Contribution of oncoproteomics to cancer biomarker discovery. Mol. Cancer 2007, 6:25.
35. Labaer J. So, you want to look for biomarkers. J. Proteome Res. 2005, 4:1053-1059.
36. Zeng X., Andrade C.A.S., Oliveira M.D.L., Sun X. Carbohydrate-protein interactions and their biosensing applications. Anal. Bioanal. Chem. 2012, 402:3161-3176.
37. Bundle D.R., Young N.M. Carbohydrate-protein interactions in antibodies and lectins. Curr. Opin. Struct. Biol. 1992, 2:666-673.
38. Goldstein I.J., Hollerman C.E., Smith E.E. Protein-carbohydrate interaction. II. Inhibition studies on the interaction of concanavalin A with polysaccharides. Biochemistry 1965, 4:876-883.
39. Kitov P.I., Sadowska J.M., Mulvey G., Armstrong G.D., Ling H., Pannu N.S., et al. Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature 2000, 403:669-672.
40. Turner G.A. N-glycosylation of serum proteins in disease and its investigation using lectins. Clin. Chim. Acta 1992, 208:149-171.
41. Wei X., Li L. Comparative glycoproteomics: approaches and applications. Brief. Funct. Genomic. Proteomic. 2008, 8:104-113.
42. Yang Z., Hancock W.S. Approach to the comprehensive analysis of glycoproteins isolated from human serum using a multi-lectin affinity column. J. Chromatogr. A 2004, 1053:79-88.
43. Monzo A., Bonn G.K., Guttman A. Lectin-immobilization strategies for affinity purification and separation of glycoconjugates. TrAC 2007, 26:423-432.
44. Yodoshi M., Oyama T., Masaki K., Kakehi K., Hayakawa T., Suzuki S. Affinity entrapment of oligosaccharides and glycopeptides using free lectin solution. Anal. Sci. 2011, 27:395-400.
45. Xiong L., Regnier F.E. Use of a lectin affinity selector in the search for unusual glycosylation on proteomics. J. Chromatogr. B 2002, 782:405-418.
46. Zhao J., Simeone D.M., Heidt D., Anderson M.A., Lubman D.M. Comparative serum glycoproteomics using lectin selected sialic acid glycoproteins with mass spectrometric analysis: application to pancreatic cancer serum. J. Proteome Res. 2006, 5:1792-1802.
47. Li B., An H.J., Kirmiz C., Lebrilla C.B., Lam K.S., Miyamoto S. Glycoproteomic analyses of ovarian cancer cell lines and sera from ovarian cancer patients show distinct glycosylation changes in individual proteins. J. Proteome Res. 2008, 7:3776-3788.
48. Kazuno S., Fujimura T., Arai T., Ueno T., Nagao K., Fujime M., et al. Multi-sequential surface plasmon resonance analysis of haptoglobin-lectin complex in sera of patients with malignant and benign prostate diseases. Anal. Biochem. 2011, 419:241-249.
49. Yang Z., Hancock W.S. Monitoring glycosylation pattern changes of glycoproteins using multi-lectin affinity chromatography. J. Chromatogr. A 2005, 1070:57-64.
50. Madera M., Mechref Y., Novotny M.V. Combining lectin microcolumns with high-resolution separation techniques for enrichment of glycoproteins and glycopeptides. Anal. Chem. 2005, 77:4081-4090.
51. Madera M., Mechref Y., Klouckova I., Novotny M.V. High-sensitivity profiling of glycoproteins from human blood serum through multiple-lectin affinity chromatography and liquid chromatography/tandem mass spectrometry. J. Chromatogr. B 2007, 845:121-137.
52. Guiochon G., Beaver L.A., Gonnord M.F., Siouffi A.M., Zakaria M. Theoretical investigation of the potentialities of the use of a multidimensional column in chromatography. J. Chromatogr. A 1983, 255:415-437.
53. Ryu J., Kim H., Lee Y., Myong N., Hwang C., Lee G., et al. The proteomics approach to find biomarkers in gastric cancer. J. Korean Med. Sci. 2003, 18:505-509.
54. Wang K., Wang R., Zhang J. Identification of tumor markers using two-dimensional electrophoresis in gastric carcinoma. World J. Gastroenterol. 2004, 10:2179-2183.
55. Lee L.Y., Thaysen-Andersen M., Baker M.S., Packer N.H., Hancock W.S., Fanayan S. Comprehensive N-glycome profiling of cultured human epithelial breast cells identifies unique secretome N-glycosylation signatures enabling tumorigenic subtype classification. J. Proteome Res. 2014, 13:4783-4795.
56. Tsai T., Wang M., Di Poto C., Hu Y., Zhou S., Zhao Y., et al. LC-MS profiling of N-glycans derived from human serum samples for biomarker discovery in hepatocellular carcinoma. J. Proteome Res. 2014, 13:4859-4868.
57. Tao S., Huang Y., Boyes B.E., Orlando R. Liquid chromatography-selected reaction monitoring (LC-SRM) approach for the separation and quantitation of sialylated N-glycans linkage isomers. Anal. Chem. 2014, 86:10584-10590.
58. Sjöström M., Ossola R., Breslin T., Rinner O., Malmström L., Schmidt A., et al. A combined shotgun and targeted mass spectrometry strategy for breast cancer biomarker discovery. J. Proteome Res. 2015, 14:2807-2818.
59. Khatri K., Staples G.O., Leymarie N., Leon D.R., Turiák L., Yu Huang, et al. Confident assignment of site-specific glycosylation in complex glycoproteins in a single step. J. Proteome Res. 2014, 13:4347-4355.
60. Morelle W., Michalski J. The mass spectrometric analysis of glycoproteins and their glycan structures. Curr. Anal. Chem. 2005, 1:29-57.
61. Zhang Z., Sun Z., Zhu J., Liu J., Huang G., Ye M., et al. High-throughput determination of the site-specific N-sialoglycan occupancy rates by differential oxidation of glycoproteins followed with quantitative glycoproteomics analysis. Anal. Chem. 2014, 86:9830-9837.
62. Mayampurath A., Song E., Mathur A., Yu C., Hammoud Z., Mechref Y., et al. Label-free glycopeptide quantification for biomarker discovery in human sera. J. Proteome Res. 2014, 13:4821-4832.
63. Budnik B.A., Lee R.S., Steen J.A.J. Global methods for protein glycosylation analysis by mass spectrometry. Biochim. Biophys. Acta 1764, 2006:1870-1880.
64. Rodríguez-Piñero A.M., Ayude D., Rodríguez-Berrocal F.J., Cadena M.P. Concanavalin A chromatography coupled to two-dimensional gel electrophoresis improves protein expression studies of the serum proteome. J. Chromatogr. B 2004, 803:337-343.
65. Drake R.R., Schwegler E.E., Malik G., Diaz J., Block T., Mehta A., et al. Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers. Mol. Cell. Proteomics 2006, 5:1957-1967.
66. Allam H., Aoki K., Benigno B.B., McDonald J.F., Mackintosh S.G., Tiemeyer M., et al. Glycomic analysis of membrane glycoproteins with bisecting glycosylation from ovarian cancer tissues reveals novel structures and functions. J. Proteome Res. 2015, 14:434-446.
67. Hamid U.M.A., Royle L., Saldova R., Radcliffe C.M., Harvey D.J., Storr S.J., et al. A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. Glycobiology 2008, 18:1105-1118.
68. Bond M.R., Kohler J.J. Chemical methods for glycoprotein discovery. Curr. Opin. Chem. Biol. 2007, 11:52-58.
69. Khidekel N., Ficarro S.B., Peters E.C., Hsieh-Wilson L.C. Exploring the O-GlcNAc proteome: direct identification of O-GlcNAc-modified proteins from the brain. Proc. Natl. Acad. Sci. 2004, 101:13132-13137.
70. Zhang H., Li X.J., Martin D.B., Aebersold R. Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat. Biotechnol. 2003, 21:660-666.
71. Li Y., Shah P., De Marzo A.M., Van Eyk J.E., Li Q., Chan D.W., et al. Identification of glycoproteins containing specific glycans using a lectin-chemical method. Anal. Chem. 2015, 87:4683-4687.
72. Liu T., Qian W., Gritsenko M.A., Camp D.G., Monroe M.E., Moore R.J., et al. Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry. J. Proteome Res. 2005, 4:2070-2080.
73. Song E., Zhu R., Hammoud Z.T., Mechref Y. LC-MS/MS quantitation of esophagus disease blood serum glycoproteins by enrichment with hydrazide chemistry and lectin affinity chromatograph. J. Proteome Res. 2014, 13:4808-4820.
74. Nwosu C., Yau H.K., Becht S. Rapid assignment of core versus antenna fucosylation types in protein N-glycosylation via procainamide labeling and tandem mass spectrometry. Anal. Chem. 2015, 87:5905-5913.
75. Wu J., Fu Z., Yan F., Ju H. Biomedical and clinical applications of immunoassays and immunosensors for tumor markers. TrAC 2007, 26:679-688.
76. Kumar S.R., Sauter E.R., Quinn T.P., Deutscher S.L. Thomsen-Friedenreich and Tn antigens in nipple fluid: carbohydrate biomarkers for breast cancer detection. Clin. Cancer Res. 2005, 11:6868-6871.
77. Zheng G.F., Patolsky F., Cui Y., Wang W.U., Lieber C.M. Multiplexed electrical detection of cancer markers with nanowire sensor arrays. Nat. Biotechnol. 2005, 10:1294-1301.
78. Le Naour F. Identification of tumor antigens by using proteomics. Methods in Molecular Biology, vol 360, Target discovery and validation reviews and protocols, vol 1. Emerging Strategies for Targets and Biomarker Discovery 2007, 327-334. M.Sioud, Humana Press Inc., Totowa, NJ.
79. Lee S.W., Hosokawa K., Kim S., Laurell T., Maeda M. Simple and robust antibody microarray-based immunoassay platform for sensitive and selective detection of PSA and hK2 toward accurate diagnosis of prostate cancer. Sens. Bio-Sens. Res. 2015, 3:105-111.
80. Singh S., Pal K., Yadav J., Tang H., Partyka K., Kletter D., et al. Upregulation of glycans containing 3' fucose in a subset of pancreatic cancers uncovered using fusion-tagged lectins. J. Proteome Res. 2015, 14:2594-2605.
81. Petricoin E.F., Paweletz C.P., Liotta L.A. Clinical applications of proteomics: proteomic pattern diagnostics. J. Mammary Gland Biol. Neoplasia 2002, 7:433-440.
82. Hanash S. Disease proteomics. Nature 2003, 422:226-232.
83. Pilobello K.T. Development of a lectin microarray for the rapid analysis of protein glycopatterns. ChemBioChem 2005, 6:1-4.
84. Narimatsu H., Sawaki H., Kuno A., Kaji H., Ito H., Ikehara Y. A strategy for discovery of cancer glyco-biomarkers in serum using newly developed technologies for glycoproteomics. FEBS J. 2010, 277:95-105.
85. Wu J., Xie X., Liu Y., He J., Benitez R., Buckanovich R.J., et al. Identification and confirmation of differentially expressed fucosylated glycoproteins in the serum of ovarian cancer patients using a lectin array and LC-MS/MS. J. Proteome Res. 2012, 11:4541-4552.
86. Pihíková D., Kasák P., Tkac J. Glycoprofiling of cancer biomarkers: label-free electrochemical lectin-based biosensors. Open Chem. 2015, 13:636-655.
87. Choi E., Loo D., Dennis J.W., O'Leary C.A., Hill M.M. High-throughput lectin magnetic bead array-coupled tandem mass spectrometry for glycoprotein biomarker discovery. Electrophoresis 2011, 32:3564-3575.
88. Yue T., Goldstein I.J., Hollingsworth M.A., Kaul K., Brand R.E., Haab B.B. The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays. Mol. Cell. Proteomics 2009, 8:1697-1707.
89. Kuno A., Kato Y., Matsuda A., Kaneko M.K., Ito H., Amano K., et al. Focused differential glycan analysis with the platform antibody-assisted lectin profiling for glycan-related biomarker verification. Mol. Cell. Proteomics 2009, 8:99-108.
90. Hirabayashi J. Concept, strategy and realization of lectin-based glycan profiling. J. Biochem. 2008, 144:139-147.
91. Nelson B.P. Multiplexed antibody arrays for the discovery and validation of glycosylated protein biomarkers. Bioanalysis 2009, 1:1431-1444.
92. Thulasiraman V., Lin S., Gheorghiu L., Lathrop J., Lomas L., Hammond D., et al. Reduction of the concentration difference of proteins in biological liquids using a library of combinatorial ligands. Electrophoresis 2005, 26:3561-3571.
93. Righetti P.G., Boschetti E., Lomas L., Citterio A. Protein Equalizer Technology*: the quest for a "democratic proteome". Proteomics 2006, 6:3980-3992.
94. Bodzon-Kulakowskaa A., Bierczynska-Krzysik A., Dylag T., Drabik A., Suder P., Nogaa M., et al. Methods for samples preparation in proteomic research. J. Chromatogr. B 2007, 849:1-31.